Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this (...)
Site référencé: The Economic Times
The Economic Times
HUDCO, IDFC First Bank among top 10 mid cap stocks bought by mutual funds in March
18/04/2025
Saurav Ghosh explains why now is the best time to explore bonds
18/04/2025
Top 5 AMCs with highest growth in AUM in January - March quarter
18/04/2025
Pak authorities make fresh effort to sell cash-strapped PIA
18/04/2025
Sensex jumps 4,700 points in 4 days of fast and furious rally. Time to ride the tide or sell on rise ?
18/04/2025
Best arbitrage mutual funds to invest in April 2025
18/04/2025
